How effective are disease-modifying drugs in delaying progression in relapsing-onset ms?
Brenner
Steven R
SR
Brown
M G
MG
Kirby
S
S
Skedgel
C
C
Fisk
J D
JD
Murray
T J
TJ
Bhan
V
V
Sketris
I S
IS
D004185:Disability Evaluation; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D000068717:Glatiramer Acetate; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use; D012107:Research Design; D016896:Treatment Outcome
D018696:Neuroprotective Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D007372:Interferons